14 October 2020 | News
To co-operate in the development and production of novel drugs, and jointly promote the R&D of innovative oncology therapies
Image credit- prnewswire
Antengene Corporation, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, and WuXi Biologics announced that they have signed a strategic cooperation Memorandum of Understanding (MoU) to co-operate in the development and production of novel drugs, and jointly promote the R&D of innovative oncology therapies.
China's cancer incidence and mortality have been increasing in recent years. Low rates of survival and access to innovative therapies are persistent obstacles to local cancer treatment. With the vision of "Treating patients beyond borders", Antengene is committed to bringing novel mechanisms of action and cutting-edge anti-tumor therapies to patients in China, the rest of Asia Pacific and around the world.
As a leading global open-access biologics technology platform, Wuxi Biologics offers end-to-end solutions based on its sophisticated R&D system and technological platform to advance the process of promoting drug R&D from concept to commercial manufacturing.
Through the collaboration, Antengene and WuXi Biologics will make full use of their extensive resources and professional capabilities to accelerate the research and development of first-in-class or best-in-class innovative cancer therapies and provide patients with high-quality and affordable treatment plans as soon as possible.
Image caption- Dr. Chris Chen(Left), CEO of WuXi Biologics, and Dr. Jay Mei (Right), Founder, Chairman and CEO of Antengene